- Home
- CCK vs MRNA Comparison
CCK vs MRNA Comparison
Compare CCK & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCK
- MRNA
- Stock Information
- Founded
- CCK 1906
- MRNA 2010
- Country
- CCK United States
- MRNA United States
- Employees
- CCK N/A
- MRNA N/A
- Industry
- CCK Containers/Packaging
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCK Industrials
- MRNA Health Care
- Exchange
- CCK Nasdaq
- MRNA Nasdaq
- Market Cap
- CCK 11.5B
- MRNA 9.8B
- IPO Year
- CCK N/A
- MRNA 2018
- Fundamental
- Price
- CCK $97.18
- MRNA $27.16
- Analyst Decision
- CCK Strong Buy
- MRNA Hold
- Analyst Count
- CCK 14
- MRNA 15
- Target Price
- CCK $118.57
- MRNA $37.15
- AVG Volume (30 Days)
- CCK 1.6M
- MRNA 10.8M
- Earning Date
- CCK 10-20-2025
- MRNA 11-06-2025
- Dividend Yield
- CCK 1.07%
- MRNA N/A
- EPS Growth
- CCK 892.53
- MRNA N/A
- EPS
- CCK 8.10
- MRNA N/A
- Revenue
- CCK $12,141,000,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- CCK $4.02
- MRNA N/A
- Revenue Next Year
- CCK $2.66
- MRNA $11.12
- P/E Ratio
- CCK $12.00
- MRNA N/A
- Revenue Growth
- CCK 3.27
- MRNA N/A
- 52 Week Low
- CCK $75.98
- MRNA $23.15
- 52 Week High
- CCK $109.48
- MRNA $56.70
- Technical
- Relative Strength Index (RSI)
- CCK 54.17
- MRNA 52.43
- Support Level
- CCK $98.06
- MRNA $24.25
- Resistance Level
- CCK $102.85
- MRNA $29.20
- Average True Range (ATR)
- CCK 2.27
- MRNA 1.44
- MACD
- CCK 0.31
- MRNA -0.03
- Stochastic Oscillator
- CCK 58.43
- MRNA 58.79
About CCK Crown Holdings Inc.
Crown Holdings is one of the world's largest producers of metal packaging. The company manufactures beverage cans, metal food cans, and closures as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.